Rivaroxaban-d4

• Description:

  Rivaroxaban-d4 (BAY 59-7939-d4) is a deuterium labeled Rivaroxaban. Rivaroxaban is a highly potent, selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM) [1][2].

• Product Name Alternative:

  BAY 59-7939-d4

• UNSPSC:

  12352005

• Hazard Statement:

  H302

• Target:

  Factor Xa

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Purity:

  98.73

• Solubility:

  10 mM in DMSO|DMSO : 50mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CC=C(Cl)S1)NC[C@H]2CN(C3=C([2H])C([2H])=C(N4C(COCC4)=O)C([2H])=C3[2H])C(O2)=O

• Molecular Formula:

  C19H14D4ClN3O5S

• Molecular Weight:

  439.91

• Precautions:

  H302

• References & Citations:

  [1]Roehrig S, et al. Discovery of the novel antithrombotic agent 5-chloro-N- ({ (5S) -2-oxo-3- [4- (3-oxomorpholin-4-yl) phenyl]-1,3-oxazolidin-5-yl}methyl) thiophene- 2-carboxamide (BAY 59-7939) : an oral, direct factor Xa inhibitor. J Med Chem. 2005 Sep 22;48 (19) |[2]Perzborn E, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005 Mar;3 (3) :514-21.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• CAS Number:

  [1132681-38-9]